New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export ABBV’s income statement to Excel — free account
AbbVie Inc.
ABBVHealthcare Drug Manufacturers General
AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024.
- Revenue
- +10.3%
- EPS
- +2,270.0%
- Free cash flow
- +9.97%
- Total debt
- +17.7%
Quarter to September 2026, against a year earlier
288.50
4.99
+1.76%
Follow ABBV
Alert me
AbbVie Inc. (ABBV) revenue by segment, product and region
Where the money comes from and where it goes
| Skyrizi | 17,562 | 28.71% |
|---|---|---|
| Rinvoq | 8,304 | 13.58% |
| Humira | 4,540 | 7.42% |
| Botox Therapeutic | 3,769 | 6.16% |
| Vraylar | 3,621 | 5.92% |
| Imbruvica | 2,869 | 4.69% |
| Venclexta | 2,792 | 4.57% |
| All other | 2,627 | 4.30% |
| Botox Cosmetic | 2,602 | 4.25% |
| Other, not broken out | 1,545 | 2.53% |
| Mavyret | 1,317 | 2.15% |
| Ubrelvy | 1,271 | 2.08% |
| Other Aesthetics | 1,265 | 2.07% |
| Qulipta | 1,036 | 1.69% |
| Other Eye Care | 1,009 | 1.65% |
| Juvederm Collection | 993 | 1.62% |
| Linzess | 907 | 1.48% |
| Elahere | 690 | 1.13% |
| Ozurdex | 493 | 0.81% |
| Vyalev | 482 | 0.79% |
| Lumigan/Ganfort | 410 | 0.67% |
| Duodopa | 381 | 0.62% |
| Epkinly | 271 | 0.44% |
| Other Neuroscience | 207 | 0.34% |
| Alphagan/Combigan | 197 | 0.32% |
| Gross margin | 70.24% | |
| Operating margin | 24.65% | |
| Pre-tax margin | 10.79% |
Revenue by product or service $m
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|
| Skyrizi | 17,562 28.71% | 11,718 20.80% | 7,763 14.29% | 5,165 8.90% | — | — | — | — | — |
| Rinvoq | 8,304 13.58% | 5,971 10.60% | 3,969 7.31% | 2,522 4.34% | — | — | — | — | — |
| Humira | 4,540 7.42% | 8,993 15.96% | 14,404 26.52% | 21,237 36.58% | 14,012 61.30% | 12,543 62.84% | 10,659 56.73% | 9,265 50.41% | 7,932 45.47% |
| Botox Therapeutic | 3,769 6.16% | 3,283 5.83% | 2,991 5.51% | 2,719 4.68% | — | — | — | — | — |
| Vraylar | 3,621 5.92% | 3,267 5.80% | 2,759 5.08% | 2,038 3.51% | — | — | — | — | — |
| Imbruvica | 2,869 4.69% | 3,347 5.94% | 3,596 6.62% | 4,568 7.87% | 754 3.30% | 0 0.00% | — | — | — |
| Venclexta | 2,792 4.57% | 2,583 4.59% | 2,288 4.21% | 2,009 3.46% | — | — | — | — | — |
| All other | 2,627 4.30% | 3,032 5.38% | 3,035 5.59% | 4,137 7.13% | 1,402 6.13% | 1,957 9.80% | 1,666 8.87% | 1,525 8.30% | 1,735 9.95% |
| Botox Cosmetic | 2,602 4.25% | 2,720 4.83% | 2,682 4.94% | 2,615 4.50% | — | — | — | — | — |
| Mavyret | 1,317 2.15% | 1,311 2.33% | 1,430 2.63% | 1,541 2.65% | — | — | — | — | — |
| Ubrelvy | 1,271 2.08% | 1,006 1.79% | 815 1.50% | 680 1.17% | — | — | — | — | — |
| Other Aesthetics | 1,265 2.07% | 1,279 2.27% | 1,234 2.27% | 1,290 2.22% | — | — | — | — | — |
| Qulipta | 1,036 1.69% | 658 1.17% | 408 0.75% | 158 0.27% | — | — | — | — | — |
| Other Eye Care | 1,009 1.65% | 1,071 1.90% | 1,239 2.28% | 747 1.29% | — | — | — | — | — |
| Juvederm Collection | 993 1.62% | 1,177 2.09% | 1,378 2.54% | 1,428 2.46% | — | — | — | — | — |
| Linzess | 907 1.48% | 954 1.69% | 1,108 2.04% | 1,035 1.78% | — | — | — | — | — |
| Elahere | 690 1.13% | 479 0.85% | 0 0.00% | 0 0.00% | — | — | — | — | — |
| Ozurdex | 493 0.81% | 494 0.88% | 472 0.87% | 428 0.74% | — | — | — | — | — |
| Vyalev | 482 0.79% | 99 0.18% | 3 0.01% | — | — | — | — | — | — |
| Lumigan/Ganfort | 410 0.67% | 429 0.76% | 432 0.80% | 514 0.89% | — | — | — | — | — |
| Duodopa | 381 0.62% | 447 0.79% | 468 0.86% | 458 0.79% | 231 1.01% | 220 1.10% | 178 0.95% | 149 0.81% | 125 0.72% |
| Epkinly | 271 0.44% | 146 0.26% | 31 0.06% | — | — | — | — | — | — |
| Other Neuroscience | 207 0.34% | 239 0.42% | 273 0.50% | 475 0.82% | — | — | — | — | — |
| Alphagan/Combigan | 197 0.32% | 248 0.44% | 272 0.50% | 346 0.60% | — | — | — | — | — |
| Restasis | — | — | — | 666 1.15% | — | — | — | — | — |
| Hcv | — | — | — | — | 1,639 7.17% | 48 0.24% | — | — | — |
| Lupron | — | — | — | — | 826 3.61% | 778 3.90% | 785 4.18% | 800 4.35% | 810 4.64% |
| Synthroid | — | — | — | — | 755 3.30% | 709 3.55% | 622 3.31% | 551 3.00% | 522 2.99% |
| Synagis | — | — | — | — | 740 3.24% | 835 4.18% | 827 4.40% | 825 4.49% | 775 4.44% |
| Kaletra | — | — | — | — | 700 3.06% | 870 4.36% | 962 5.12% | 1,013 5.51% | 1,170 6.71% |
| Andro Gel | — | — | — | — | 694 3.04% | 934 4.68% | 1,035 5.51% | 1,152 6.27% | 874 5.01% |
| Creon | — | — | — | — | 632 2.76% | 516 2.59% | 412 2.19% | 353 1.92% | 332 1.90% |
| Sevoflurane | — | — | — | — | 474 2.07% | 550 2.76% | 568 3.02% | 602 3.28% | 665 3.81% |
| Dyslipidemia Products | — | — | — | — | — | — | 1,076 5.73% | 2,145 11.67% | 2,504 14.35% |
| Other, not broken out | 1,545 2.53% | 1,383 2.46% | 1,268 2.33% | 1,278 2.20% | — | — | — | — | — |
| Revenue | 61,160 | 56,334 | 54,318 | 58,054 | 22,859 | 19,960 | 18,790 | 18,380 | 17,444 |
Revenue by region $m
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | 46,603 76.20% | 43,029 76.38% | 41,883 77.11% | 45,713 78.74% | 43,510 77.42% | 34,879 76.15% | 23,907 71.87% | 21,524 65.72% | 18,251 64.68% | 15,947 62.20% | 13,561 59.32% | 10,845 54.33% | 10,181 54.18% | 10,435 56.77% | 9,712 55.68% |
| All other countries | 5,759 9.42% | 5,449 9.67% | 5,042 9.28% | 4,837 8.33% | 4,761 8.47% | 3,977 8.68% | 3,566 10.72% | 3,863 11.79% | 4,080 14.46% | 3,885 15.15% | 4,001 17.50% | 3,896 19.52% | 3,671 19.54% | 2,776 15.10% | 2,674 15.33% |
| Germany | 1,738 2.84% | 1,465 2.60% | 1,266 2.33% | 1,340 2.31% | 1,223 2.18% | 1,049 2.29% | 909 2.73% | 1,292 3.94% | 1,157 4.10% | 1,104 4.31% | 1,082 4.73% | 1,035 5.19% | 911 4.85% | 756 4.11% | 701 4.02% |
| Japan | 1,274 2.08% | 1,122 1.99% | 1,008 1.86% | 956 1.65% | 1,090 1.94% | 1,198 2.62% | 1,211 3.64% | 1,591 4.86% | 764 2.71% | 770 3.00% | 599 2.62% | 581 2.91% | 625 3.33% | 718 3.91% | 616 3.53% |
| Canada | 1,222 2.00% | 1,088 1.93% | 1,076 1.98% | 1,159 2.00% | 1,397 2.49% | 1,159 2.53% | 813 2.44% | 730 2.23% | 659 2.34% | 624 2.43% | 551 2.41% | 551 2.76% | 538 2.86% | 500 2.72% | 446 2.56% |
| China | 1,006 1.64% | 917 1.63% | 950 1.75% | 912 1.57% | 857 1.52% | 471 1.03% | 195 0.59% | 152 0.46% | — | — | — | — | — | — | — |
| France | 806 1.32% | 776 1.38% | 780 1.44% | 787 1.36% | 936 1.67% | 797 1.74% | 695 2.09% | 783 2.39% | 730 2.59% | 713 2.78% | 597 2.61% | 584 2.93% | 540 2.87% | 500 2.72% | 516 2.96% |
| United Kingdom | 626 1.02% | 522 0.93% | 417 0.77% | 462 0.80% | 497 0.88% | 509 1.11% | 372 1.12% | 855 2.61% | 807 2.86% | 776 3.03% | 688 3.01% | 722 3.62% | 606 3.23% | 552 3.00% | 496 2.84% |
| Spain | 609 1.00% | 528 0.94% | 501 0.92% | 506 0.87% | 519 0.92% | 453 0.99% | 472 1.42% | 611 1.87% | 521 1.85% | 589 2.30% | 618 2.70% | 534 2.68% | 543 2.89% | 525 2.86% | 569 3.26% |
| Italy | 580 0.95% | 511 0.91% | 484 0.89% | 444 0.76% | 506 0.90% | 379 0.83% | 372 1.12% | 652 1.99% | 475 1.68% | 523 2.04% | 452 1.98% | 432 2.16% | 404 2.15% | 408 2.22% | 428 2.45% |
| Brazil | 478 0.78% | 464 0.82% | 439 0.81% | 430 0.74% | 368 0.65% | 406 0.89% | 359 1.08% | 350 1.07% | 410 1.45% | 355 1.38% | 376 1.64% | 435 2.18% | 439 2.34% | 434 2.36% | 382 2.19% |
| Australia | 459 0.75% | 463 0.82% | 472 0.87% | 508 0.88% | 533 0.95% | 527 1.15% | 395 1.19% | 350 1.07% | — | — | — | — | — | — | — |
| Netherlands | — | — | — | — | — | — | — | — | 362 1.28% | 352 1.37% | 334 1.46% | 345 1.73% | 332 1.77% | 776 4.22% | 904 5.18% |
| Revenue | 61,160 | 56,334 | 54,318 | 58,054 | 56,197 | 45,804 | 33,266 | 32,753 | 28,216 | 25,638 | 22,859 | 19,960 | 18,790 | 18,380 | 17,444 |